My common sense is tingling.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We could see a penny today if folks would show a little patience.
Latest Xconomy article on WASM just out today:
CytoBiosciences Buys Fellow Targeted Tech Company BioDTech for Stock.
https://xconomy.com/texas/2018/11/28/cytobiosciences-buys-fellow-targeted-tech-company-biodtech-for-stock/
Picked up a few .004's this morning.
Only 325,000 market cap seems a bit low, doesn't it?
This Richard Chiang is kind of a big player.
https://www.nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=Wq21EZCR%252f2g0q0pFwQF3hg%253d%253d
Nice share structure:
Authorized Shares 150,000,000 11/27/2018
Outstanding Shares 81,145,933 11/27/2018
Restricted 51,000,342 11/27/2018
Unrestricted 30,145,591 11/27/2018
Held at DTC 30,042,443 11/27/2018
https://www.otcmarkets.com/stock/CNHC/security
We'll be above a penny before too long.
Should start seeing more tax loss selling soon.
https://www.investopedia.com/articles/personal-finance/100515/heres-how-deduct-your-stock-losses-your-tax-bill.asp
re: R/S. Besides the adjusted jump in price, the new share structure will be tighter than a duck's ass:
1 for 5 gives us an O/S of 10,959,752 and a tiny float of about 152,350
1 for 10 gives us an O/S of only 5,479,876 and a micro float of about 76,175
The Reverse Stock Split will affect all of the Stockholders uniformly and will not affect any stockholder’s percentage ownership interests in the Company.
https://www.otcmarkets.com/filing/html?id=13074992&guid=Yp7bUqZeHmNrTyh
I'd like to see the company promote itself before (and right after) the reverse split. The current share price of $0.25 (13,528,470 market cap) is ridiculously undervalued.
Direct quote from the pre 14c filing:
I agree. It seems like a good question to ask Dr. Garvin.
Well, just off the top of my head, it raises the price per share and tightens the share structure making the stock much more attractive to institutional investors, the company becomes price compliant for a serious stock exchange like NASDAQ and makes it impossible for an unwanted hostile takeover all without destroying current shareholders in the process.
So, we're finally graduating to the big leagues.
Add BioDTech, Inc, to our ever growing list of acquisitions bringing more value to the company.
Usually, I'm no fan of reverse splits but a 1 for 5 up to 1 for 10 isn't bad at all especially for a biotech conglomerate.
(WASM) soon to be InventaBiotech, Inc. should be looking to up-list to a serious stock exchange before long.
HDIH was $4.00 right after the reverse split.
Quick, somebody slap the ask. LOL!
Hey Quintessence, thanks for finding and posting that.
It's always good to hear things are still very much in motion and happening behind the scenes.
The article hints at some very big things to come. I can see CytoBioscience selling their propriety tech not just in the US but globally in such a fast-growing market and a couple more acquisitions sending the company's value skyrocketing.
I sincerely hope everyone here can stick around long enough for the big payoff that's sure to happen. Easy 10-20 bagger from these ridiculous prices in the not too distant future. Then crazy money a little further down the road.
On a side note, I've been distracted lately so if any of you other mods would like to update or modify the iBox please feel free.
I've always considered myself to be a patient man but have to admit CytoBioscience is testing that patience. Dr. Garvin left me with the impression that some form of a press release or news report would coincide or directly follow the updated filings. It would appear that was not the case.
Tax-loss selling season is upon us so one would think the sooner the better for the company to spread the word about this amazing investment.
Making up absurd nonsense about FINRA means nothing. The court hearing isn't too far off so maybe try exercising some patience.
Actually, it's rare that there's ever any "issue". FINRA processes name and ticker changes every day.
I have no idea how anyone could make wild claims like there would be an issue much less "more than one" without having insider information which of course you do not.
How did you just go from "FINRA takes 6 to 9 months to verify a company is compliant to trade" to "30-35 days for FINRA responses"?
That's an extremely big difference.
In my 10+ years of experience, FINRA usually takes from 1 to 3 weeks to approve a symbol change etc.
The only timeline folks should be concerned about is the 30 days until the custodianship hearing. Everything else is speculation.
Have a good evening.
LOL! That's complete and total bullshit.
Ugly, and it's just going to get worse.
ASCC has a crazy attractive share structure:
Authorized Shares
250,000,000 07/31/2018
Outstanding Shares
5,427,157 07/31/2018
Restricted
1,289,901 07/31/2018
Unrestricted
4,137,256 07/31/2018
Held at DTC
3,908,846 07/31/2018
Float
1,379,685 11/16/2015
https://www.otcmarkets.com/stock/ASCC/security
This has a ton of potential.
NULF getting some love on merger news:
NuLife Announces Merger Agreement with Two Louisiana Electronic Security Firms | 08/09/2018
https://www.otcmarkets.com/stock/NULF/news/NuLife-Announces-Merger-Agreement-with-Two-Louisiana-Electronic-Security-Firms?id=200418
Authorized Shares
475,000,000
Outstanding Shares
40,914,64
Restricted
10,616,627
Unrestricted
30,298,020
Held at DTC
11,149,061
Float
6,988,734
A blind bid like that is usually a market maker or "institutional" loading.
What doesn't make sense to me is the short-sighted selling. Just crazy.
Some weekend reading, WASM Reverse-Merger with CytoBioscience DD:
8-K showing about $40 million in assets valuation with the shares that were exchanged for the merger. https://backend.otcmarkets.com/otcapi/company/sec-filings/12644875/content/html
CytoBioscience, Inc. website: http://cytobioscience.com/
The latest 10-Q including revenue and a significant number of patents is late because they're doing fully audited financials for CytoBioscience and SolubleBioScience both of which are being rolled into WASM.
https://backend.otcmarkets.com/otcapi/company/sec-filings/12760401/content/html
Which turns out to be a chance for others to get in before The Street.
Share structure:
Authorized Shares 50,000,000
Outstanding Shares 11,017,402
Float 761,750
https://www.otcmarkets.com/stock/WASM/security
Shares have to be issued for the merger but they're all restricted for up to 2 years per lock-up agreement.
https://www.lawinsider.com/contracts/69F0a8ZWXoUh5pnCOUXqbR/westmountain-asset-management-inc/1421603/2018-03-23
After the merger is finalized:
A/S 100,000,000
O/S 54,382,961 (Over 53 million are restricted)
Float 761,750
CytoBioscience's instrument is used by the FDA in its safety pharmacology studies and there isn’t any real competition.
Our patch clamp robot is the gold standard in accurate and reliable data while saving massive amounts of time and money.
Video: https://youtu.be/g2yahi4VJJs
The base CytoPatch unit sells for $175,000, and CytoBioScience also sells microchips, buffers, solutions, cells, and specific types of shipping containers to researchers on a recurring basis, Garvin says. CytoBioscience, which changed its name last year, was founded in Germany and moved to San Antonio in 2015. Regulatory filings show CytoBioScience had raised about $15.8 million as of August 2016.
https://www.xconomy.com/texas/2017/08/01/cytobioscience-plans-merger-with-publicly-traded-skyline-medical/
They just did a $1.5 million non-dilutive offering so they're flush with cash now. ($1.53 million equity round of funding)
https://www.xconomy.com/texas/2018/03/19/cytobioscience-raises-1-5m-for-intended-merger-document-says/
From the 8K - "Each of these revenue-generating segments; instruments, consumables and contract research, is a leader in its technology and in its capacity. Having undergone years of testing, starting, restarting, and honing its development into the cutting edge it is today, the Company is experiencing accelerating revenue growth and is well-positioned to reach its potential."
Also: "The market is experiencing strong growth, driven by both regulation and rising demand for outsourced safety pharmacological work.
The company is engaged with both private and public partners globally, including the FDA."
Back in Aug 1, 2017, CytoBioscience came close to merging with Skyline Medical now Precision Therapeutics Inc. NASDAQ (AIPT)
They bragged that CytoBioscience had a current backlog of $6 million in orders and anticipated contract research work.
http://investors.skylinemedical.com/index.php/news-releases/news-release-details/skyline-medical-signs-binding-letter-intent-merger-transaction
CytoBioscience's latest acquisition: SolubleBioScience f.k.a. Soluble Therapeutics https://solublebioscience.com/
CytoBioscience, Inc. has purchased Birmingham, Alabama-based Soluble Therapeutics and will move the company’s operations to its San Antonio location.
Details of the multi-million dollar purchase price were not disclosed.
https://solublebioscience.com/former-german-firm-bringing-more-biotech-business-to-san-antonio/
https://www.businesswire.com/news/home/20161220005098/en/Soluble-Therapeutics-Acquired-CytoBioscience
Some past DD: http://therivardreport.com/german-biotech-company-moving-to-san-antonio/
CytoBioscience's Revenue, Funding and Acquisitions
https://www.owler.com/company/cytobioscience
Estimated Revenue: $15M
"CytoBioscience is a manufacturer of medical instrumentation that supports ion channel research and individualized treatment modalities.
James Garvin is the CEO of CytoBioscience and has an approval rating of CytoBioscience has raised $17.4M in funding."
CytoBioScience has 4 locations:
San Antonio, TX
New Orleans, LA
Birmingham, AL
Cologne, Germany
The officers and (B Of D) are all giants in their fields:
James R. Garvin, PhD Chief Executive Officer, President, and Director
Thomas Knott, PhD Chief Science Officer and Director
Henry C. Bourg, CPA Chief Financial Officer
Paul Castella, PhD Director
Ian Clements Director
Alan Dean Director
Shing Leong Hui Director
Sue Lynn Hui Director
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140673149
Contact info:
Dr. James Garvin, PhD
j.garvin@cytobioscience.com
info@CytoBioScience.com
(210)-767-2727
Here ya go: Securities Transfer Corp at (469) 633-0101
This is getting ridiculous.
Great news! Generated a whopping 98 shares volume in the first hour of trading.
Better start pumping harder.
Just by how hard (SANT) is being plugged, pumped, and promoted you'd think the share price would be at $20 by now!
Whatever they're paying these guys it's WAY too much. Pretty piss poor price action. Glad I'm not holding much.
WASM (761,750 Float) reverse-merger with CytoBioscience, updated DD:
8-K showing about $40 million in assets valuation with the shares that were exchanged for the merger. https://backend.otcmarkets.com/otcapi/company/sec-filings/12644875/content/html
CytoBioscience, Inc. website: http://cytobioscience.com/
The latest 10-Q including revenue and a significant number of patents is late because they're doing fully audited financials for CytoBioscience and SolubleBioScience both of which are being rolled into WASM.
https://backend.otcmarkets.com/otcapi/company/sec-filings/12760401/content/html
Which turns out to be a chance for others to get in before The Street.
Share structure:
Authorized Shares 50,000,000
Outstanding Shares 11,017,402
Float 761,750
https://www.otcmarkets.com/stock/WASM/security
Shares have to be issued for the merger but they're all restricted for up to 2 years per lock-up agreement.
https://www.lawinsider.com/contracts/69F0a8ZWXoUh5pnCOUXqbR/westmountain-asset-management-inc/1421603/2018-03-23
After the merger is finalized:
A/S 100,000,000
O/S 54,382,961 (Over 53 million are restricted)
Float 761,750
CytoBioscience's instrument is used by the FDA in its safety pharmacology studies and there isn’t any real competition.
Our patch clamp robot is the gold standard in accurate and reliable data while saving massive amounts of time and money.
Video: https://youtu.be/g2yahi4VJJs
The base CytoPatch unit sells for $175,000, and CytoBioScience also sells microchips, buffers, solutions, cells, and specific types of shipping containers to researchers on a recurring basis, Garvin says. CytoBioscience, which changed its name last year, was founded in Germany and moved to San Antonio in 2015. Regulatory filings show CytoBioScience had raised about $15.8 million as of August 2016.
https://www.xconomy.com/texas/2017/08/01/cytobioscience-plans-merger-with-publicly-traded-skyline-medical/
They just did a $1.5 million non-dilutive offering so they're flush with cash now. ($1.53 million equity round of funding)
https://www.xconomy.com/texas/2018/03/19/cytobioscience-raises-1-5m-for-intended-merger-document-says/
From the 8K - "Each of these revenue-generating segments; instruments, consumables and contract research, is a leader in its technology and in its capacity. Having undergone years of testing, starting, restarting, and honing its development into the cutting edge it is today, the Company is experiencing accelerating revenue growth and is well-positioned to reach its potential."
Also: "The market is experiencing strong growth, driven by both regulation and rising demand for outsourced safety pharmacological work.
The company is engaged with both private and public partners globally, including the FDA."
Back in Aug 1, 2017, CytoBioscience came close to merging with Skyline Medical now Precision Therapeutics Inc. NASDAQ (AIPT)
They bragged that CytoBioscience had a current backlog of $6 million in orders and anticipated contract research work.
http://investors.skylinemedical.com/index.php/news-releases/news-release-details/skyline-medical-signs-binding-letter-intent-merger-transaction
CytoBioscience's latest acquisition: SolubleBioScience f.k.a. Soluble Therapeutics https://solublebioscience.com/
CytoBioscience, Inc. has purchased Birmingham, Alabama-based Soluble Therapeutics and will move the company’s operations to its San Antonio location.
Details of the multi-million dollar purchase price were not disclosed.
https://solublebioscience.com/former-german-firm-bringing-more-biotech-business-to-san-antonio/
https://www.businesswire.com/news/home/20161220005098/en/Soluble-Therapeutics-Acquired-CytoBioscience
Some past DD: http://therivardreport.com/german-biotech-company-moving-to-san-antonio/
Hoovers and Manta both have educated low-ball guesses of at least $5 million in revenue. http://www.hoovers.com/company-information/cs/company-profile.cytocentrics_inc.c7a5e565a9d4e534.html
https://www.manta.com/c/mhh5jt8/cytobioscience
CytoBioScience has 4 locations:
San Antonio, TX
New Orleans, LA
Birmingham, AL
Cologne, Germany
The officers and (B Of D) are all giants in their fields:
James R. Garvin, PhD Chief Executive Officer, President, and Director
Thomas Knott, PhD Chief Science Officer and Director
Henry C. Bourg, CPA Chief Financial Officer
Paul Castella, PhD Director
Ian Clements Director
Alan Dean Director
Shing Leong Hui Director
Sue Lynn Hui Director
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140673149
Contact info:
Dr. James Garvin, PhD
j.garvin@cytobioscience.com
info@CytoBioScience.com
(210)-767-2727
WASM (761,750 Float) Reverse-Merger with CytoBioscience, Updated DD:
8-K showing about $40 million in assets valuation with the shares that were exchanged for the merger. https://backend.otcmarkets.com/otcapi/company/sec-filings/12644875/content/html
CytoBioscience, Inc. website: http://cytobioscience.com/
The latest 10-Q including revenue and a significant number of patents is late because they're doing fully audited financials for CytoBioscience and SolubleBioScience both of which are being rolled into WASM.
https://backend.otcmarkets.com/otcapi/company/sec-filings/12760401/content/html
Which turns out to be a chance for others to get in before The Street.
Share structure:
Authorized Shares 50,000,000
Outstanding Shares 11,017,402
Float 761,750
https://www.otcmarkets.com/stock/WASM/security
Shares have to be issued for the merger but they're all restricted for up to 2 years per lock-up agreement.
https://www.lawinsider.com/contracts/69F0a8ZWXoUh5pnCOUXqbR/westmountain-asset-management-inc/1421603/2018-03-23
After the merger is finalized:
A/S 100,000,000
O/S 54,382,961 (Over 53 million are restricted)
Float 761,750
CytoBioscience's instrument is used by the FDA in its safety pharmacology studies and there isn’t any real competition.
Our patch clamp robot is the gold standard in accurate and reliable data while saving massive amounts of time and money.
Video: https://youtu.be/g2yahi4VJJs
The base CytoPatch unit sells for $175,000, and CytoBioScience also sells microchips, buffers, solutions, cells, and specific types of shipping containers to researchers on a recurring basis, Garvin says. CytoBioscience, which changed its name last year, was founded in Germany and moved to San Antonio in 2015. Regulatory filings show CytoBioScience had raised about $15.8 million as of August 2016.
https://www.xconomy.com/texas/2017/08/01/cytobioscience-plans-merger-with-publicly-traded-skyline-medical/
They just did a $1.5 million non-dilutive offering so they're flush with cash now. ($1.53 million equity round of funding)
https://www.xconomy.com/texas/2018/03/19/cytobioscience-raises-1-5m-for-intended-merger-document-says/
From the 8K - "Each of these revenue-generating segments; instruments, consumables and contract research, is a leader in its technology and in its capacity. Having undergone years of testing, starting, restarting, and honing its development into the cutting edge it is today, the Company is experiencing accelerating revenue growth and is well-positioned to reach its potential."
Also: "The market is experiencing strong growth, driven by both regulation and rising demand for outsourced safety pharmacological work.
The company is engaged with both private and public partners globally, including the FDA."
Back in Aug 1, 2017, CytoBioscience came close to merging with Skyline Medical now Precision Therapeutics Inc. NASDAQ (AIPT)
They bragged that CytoBioscience had a current backlog of $6 million in orders and anticipated contract research work.
http://investors.skylinemedical.com/index.php/news-releases/news-release-details/skyline-medical-signs-binding-letter-intent-merger-transaction
CytoBioscience's latest acquisition: SolubleBioScience f.k.a. Soluble Therapeutics https://solublebioscience.com/
CytoBioscience, Inc. has purchased Birmingham, Alabama-based Soluble Therapeutics and will move the company’s operations to its San Antonio location.
Details of the multi-million dollar purchase price were not disclosed.
https://solublebioscience.com/former-german-firm-bringing-more-biotech-business-to-san-antonio/
https://www.businesswire.com/news/home/20161220005098/en/Soluble-Therapeutics-Acquired-CytoBioscience
Some past DD: http://therivardreport.com/german-biotech-company-moving-to-san-antonio/
Hoovers and Manta both have educated low-ball guesses of at least $5 million in revenue. http://www.hoovers.com/company-information/cs/company-profile.cytocentrics_inc.c7a5e565a9d4e534.html
https://www.manta.com/c/mhh5jt8/cytobioscience
CytoBioScience has 4 locations:
San Antonio, TX
New Orleans, LA
Birmingham, AL
Cologne, Germany
The officers and (B Of D) are all giants in their fields:
James R. Garvin, PhD Chief Executive Officer, President, and Director
Thomas Knott, PhD Chief Science Officer and Director
Henry C. Bourg, CPA Chief Financial Officer
Paul Castella, PhD Director
Ian Clements Director
Alan Dean Director
Shing Leong Hui Director
Sue Lynn Hui Director
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140673149
Contact info:
Dr. James Garvin, PhD
j.garvin@cytobioscience.com
info@CytoBioScience.com
(210)-767-2727
SAGD making a move on news just out:
South American Gold Corp to Change Name to Sativa Growth International and Discusses Opportunities Within the Global Cannabis MarketPress Release | 06/28/2018
https://www.otcmarkets.com/stock/SAGD/news/South-American-Gold-Corp-to-Change-Name-to-Sativa-Growth-International-and-Discusses-Opportunities-Within-the-Global-Can?id=196792
You're welcome!
WASM (761,750 Float) and CytoBioscience, Inc. Reverse-Merger DD:
8-K showing about $40 million in assets valuation with the shares that were exchanged for the merger. https://backend.otcmarkets.com/otcapi/company/sec-filings/12644875/content/html
CytoBioscience, Inc. website: http://cytobioscience.com/
The latest 10-Q including revenue and a significant number of patents is late because they're doing fully audited financials for CytoBioscience and SolubleBioScience both of which are being rolled into WASM.
https://backend.otcmarkets.com/otcapi/company/sec-filings/12760401/content/html
Which turns out to be a chance for others to get in before The Street.
Share structure:
Authorized Shares 50,000,000
Outstanding Shares 11,017,402
Float 761,750
https://www.otcmarkets.com/stock/WASM/security
Shares have to be issued for the merger but they're all restricted for up to 2 years per lock-up agreement.
https://www.lawinsider.com/contracts/69F0a8ZWXoUh5pnCOUXqbR/westmountain-asset-management-inc/1421603/2018-03-23
After the merger is finalized:
A/S 100,000,000
O/S 54,382,961 (Over 53 million are restricted)
Float 761,750
CytoBioscience's instrument is used by the FDA in its safety pharmacology studies and there isn’t any real competition.
Our patch clamp robot is the gold standard in accurate and reliable data while saving massive amounts of time and money.
Video: https://youtu.be/g2yahi4VJJs